SCHEMBL15911724

SCHEMBL15911724

N[C@@H](CO)C(=O)OC(=O)[C@@H](N)Cc1cnc[nH]1

nearest known ligand 0.63

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.63
SLC7A5 Q01650 1/20 0.63
HRH4 Q9H3N8 3/20 0.49
HRH3 Q9Y5N1 3/20 0.49
ALDH1A1 P00352 2/20 0.49
MEN1 O00255 1/20 0.49
GLA P06280 1/20 0.49
KMT2A Q03164 1/20 0.49
CYP1A2 P05177 1/20 0.49
NFKB1 P19838 1/20 0.49
THPO P40225 1/20 0.49
LMNA P02545 1/20 0.47
APEX1 P27695 1/20 0.47
BLM P54132 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1537285 0.94 CYP3A4 (0.71) CYP3A4SLC7A5HRH4HRH3ALDH1A1
SCHEMBL163444 0.94 CYP3A4 (0.71) CYP3A4SLC7A5HRH4HRH3ALDH1A1
Hydrochloric Acid SCHEMBL28331180 0.92 CYP3A4 (0.69) CYP3A4SLC7A5HRH4HRH3ALDH1A1
SCHEMBL9083164 0.88 CYP3A4 (0.63) CYP3A4SLC7A5HRH4HRH3ALDH1A1
SCHEMBL9082370 0.88 CYP3A4 (0.63) CYP3A4SLC7A5HRH4HRH3ALDH1A1
SCHEMBL28328192 0.88 CYP3A4 (0.67) CYP3A4SLC7A5HRH4HRH3ALDH1A1
SCHEMBL23756950 0.87 CYP3A4 (0.61) CYP3A4SLC7A5HRH4HRH3ALDH1A1
SCHEMBL1673289 0.87 CYP3A4 (0.61) CYP3A4SLC7A5HRH4HRH3ALDH1A1
Sulfuric Acid SCHEMBL9797625 0.87 CYP3A4 (0.61) CYP3A4SLC7A5HRH4HRH3ALDH1A1
SCHEMBL3457999 0.87 CYP3A4 (0.61) CYP3A4SLC7A5HRH4HRH3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1794323-B1 IN VIVO INCORPORATION OF ALKYNYL AMINO ACIDS INTO PROTEINS IN EUBACTERIA SCRIPPS RESEARCH INST (US) 2014-08-06 EP claimed
US-20240197882-A1 HUMANIZED ANTI-SIALYL-TN GLYCAN ANTIBODIES AND USES THEREOF RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2024-06-20 US disclosed
EP-4326777-A1 HUMANIZED ANTI-SIALYL-TN GLYCAN ANTIBODIES AND USES THEREOF Ramot at Tel-Aviv University Ltd. (IL) 2024-02-28 EP disclosed
US-20240043561-A1 HUMANIZED ANTIBODIES AND FRAGMENTS THEREOF BINDING TO CARBOHYDRATE ANTIGENS AND USES THEREOF RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2024-02-08 US disclosed
EP-4251653-A1 HUMANIZED ANTIBODIES AND FRAGMENTS THEREOF BINDING TO CARBOHYDRATE ANTIGENS AND USES THEREOF Ramot at Tel-Aviv University Ltd. (IL) 2023-10-04 EP disclosed
US-20230174664-A1 ANTIBODIES TO CARBOHYDRATE ANTIGENS RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2023-06-08 US disclosed
US-20230058044-A1 CHIMERIC ANTIGEN RECEPTOR TO CARBOHYDRATE ANTIGENS UNIV RAMOT (IL) 2023-02-23 US disclosed
CN-115702892-A Application of serine in preparation of medicine for preventing and/or treating acute pancreatitis 四川大学华西医院 2023-02-17 CN disclosed
EP-4065605-A1 ANTIBODIES TO CARBOHYDRATE ANTIGENS Ramot at Tel-Aviv University Ltd. (IL) 2022-10-05 EP disclosed
WO-2022113066-A1 HUMANIZED ANTIBODIES AND FRAGMENTS THEREOF BINDING TO CARBOHYDRATE ANTIGENS AND USES THEREOF RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2022-06-02 WO disclosed
WO-2021105988-A1 ANTIBODIES TO CARBOHYDRATE ANTIGENS RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2021-06-03 WO disclosed
WO-2021105989-A1 CHIMERIC ANTIGEN RECEPTOR TO CARBOHYDRATE ANTIGENS RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2021-06-03 WO disclosed
US-9783783-B2 Compositions and methods for the expansion of stem cells CORNELL UNIVERSITY (US) 2017-10-10 US disclosed
US-20150368613-A1 COMPOSITIONS AND METHODS FOR THE EXPANSION OF STEM CELLS CORNELL UNIVERSITY 2015-12-24 US disclosed
WO-2014120714-A1 COMPOSITIONS AND METHODS FOR THE EXPANSION OF STEM CELLS CORNELL UNIVERSITY (US) 2014-08-07 WO disclosed
EP-1794323-B1 IN VIVO INCORPORATION OF ALKYNYL AMINO ACIDS INTO PROTEINS IN EUBACTERIA SCRIPPS RESEARCH INST (US) 2014-08-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240043561-A1 HUMANIZED ANTIBODIES AND FRAGMENTS THEREOF BINDING TO CARBOHYDRATE ANTIGENS AND USES THEREOF CD47, FCGR2A, FCGR3B CYP3A4 4394/4885SLC7A5 2932/4885HRH4 973/4885
US-20230174664-A1 ANTIBODIES TO CARBOHYDRATE ANTIGENS SSB, FCGR3B, FCGR2A CYP3A4 4872/4885SLC7A5 2049/4885HRH4 2474/4885
US-20230058044-A1 CHIMERIC ANTIGEN RECEPTOR TO CARBOHYDRATE ANTIGENS CD47, FCGR2A, CD2 CYP3A4 4632/4885SLC7A5 2263/4885HRH4 1935/4885
US-20240197882-A1 HUMANIZED ANTI-SIALYL-TN GLYCAN ANTIBODIES AND USES THEREOF FUT5, SIGLEC7, CD44 CYP3A4 2740/4885SLC7A5 1097/4885HRH4 540/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.